Twists and turns to translating 4-1BB cancer immunotherapy

Sci Transl Med. 2019 Jun 12;11(496):eaax4738. doi: 10.1126/scitranslmed.aax4738.

Authors

Miguel F Sanmamed^{1

2

3

4}, Iñaki Etxeberría¹, Itziar Otano¹, Ignacio Melero^{5

2

3

4}

Affiliations

¹ Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.
² Clínica Universidad de Navarra, Pamplona, Spain.
³ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
⁴ Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.
⁵ Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain. imelero@unav.es.

PMID: 31189719
DOI: 10.1126/scitranslmed.aax4738

Abstract

Previous shortcomings of CD137-targeted immunotherapy may be overcome by engineered bispecific agents (Claus et al, this issue).

Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Publication types

Research Support, Non-U.S. Gov't
Review
Comment

MeSH terms

Antibodies, Bispecific*
Humans
Immunotherapy
Neoplasms*
T-Lymphocytes

Substances

Antibodies, Bispecific